Other information on SPTA (3/4, unch):
At June 30, 1997, the company had a cash balance of $7,813,824 and working capital of $7,457,699. In addition, shareholders' equity was $8,119,128, and there were 10,115,434 shares of common stock outstanding. Taken directly from biz.yahoo.com
As of March 31, 1997, the Company had cash and cash equivalents of $9,001,586, accounts payable and accrued expenses of $597,552, and working capital of $8,579,793. The outstanding Series B' Preferred Stock is currently convertible into 9,455,947 shares of Common Stock.http://sec.yahoo.com/e/97/05/14/spta.html
As of December 31, 1996, the Company had cash and cash equivalents of $10,246,812, accounts payable and accrued expenses of $629,497, and working capital of $9,700,066. Class C Warrants to purchase 11,309,722 shares of Common Stock are currently outstanding and are redeemable under certain conditions after August 23, 1997. Each Class C Warrant has a five year term. sec.yahoo.com
As of September 30, 1996, the Company had cash and cash equivalents of $11,534,906, accounts payable and accrued expenses of $365,849, and working capital of $11,238,328. sec.yahoo.com
------
Sparta Pharmaceuticals Inc. Announces the Appointment of Dr. Martin
Rose to Vice President, Clinical and Regulatory Affairs, 9/18/97.
"Rose has broad and in-depth experience in the pharmaceutical industry, most recently as vice president, Drug Development of Quintiles Worldwide Strategic Consulting. Previously, he was with Alpha 1 Biomedicals Inc. where he was senior vice president, Clinical and Regulatory Affairs. Rose was also senior director, Government Affairs for Genentech Inc.
Prior to these positions, he was group leader for the Division of Cardio-Renal Drug Products in the Food and Drug Administration." biz.yahoo.com
------
Sparta Pharmaceuticals Inc. Announces Award of $750,000, 9/22/97.
biz.yahoo.com
Philip |
